PT027 (albuterol/budesonide) is a potential first-in-class inhaled, fixed-dose combination of the short-acting beta2-agonist albuterol and budesonide, an inhaled corticosteroid.

Marketed in the past by AstraZeneca as Pulmicort, budesonide is an off-patent inhaled steroid and could be used to prevent the risk of people getting seriously ill with the disease, if taken ...

and budesonide, a corticosteroid, and has been developed in a pressurised metered-dose inhaler (pMDI) using AstraZeneca’s Aerosphere delivery technology. Outside of the US, Airsupra is also approved ...

Breztri will be the first inhaler in AstraZeneca’s portfolio to use ... It is a fixed-dose combination of a corticosteroid ...

Get detailed information on Budesonide, including pronunciation ... Maintenance: 6 mg once daily, up to 3 months. Inhalation Asthma As metered dose inhaler: 400 mcg/day in 2 divided doses ...

This combination drug is used to treat chronic obstructive pulmonary disease in adults, relieving symptoms and preventing ...